Transcranial Pulse Stimulation (TPS) in Post-COVID-19
NCT06178952, Not applicable, Recruiting, Medical University of Vienna
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Transcranial Pulse Stimulation (TPS) in Post-COVID-19 | ClinicalTrials.gov |
| NCT number | NCT06178952 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 102 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Medical University of Vienna | ClinicalTrials.gov |
| Conditions | Post-COVID-19 Syndrome, Fatigue | ClinicalTrials.gov |
| Interventions | Transcranial pulse stimulation Verum, Transcranial pulse stimulation Sham | ClinicalTrials.gov |
| First posted | 2023-12-21 | ClinicalTrials.gov |
| Last updated | 2025-12-23 | ClinicalTrials.gov |
Registered outcomes 15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Fatigue Impact Scale (FIS) | Baseline - 1 week after stimulation - 1 month after stimulation | The Fatigue Impact Scale (Fisk et al., 1994) is an instrument to measure the impact of fatigue symptoms. This self-report measure consists of 40 items divided into three subscales: cognitive functioning (10 items), physical functioning (10 items) and psychosocial functioning (20 items). In the validated German version, the statements are scored from 0-4 (0=never, 4=very often) leading to a total score of 0-160. | ClinicalTrials.gov |
| Secondary | Beck Depression Inventory (BDI-II) | Baseline - 1 week after stimulation - 1 month after stimulation | The Beck Depression Inventory (BDI-II) is one of the most widely used instruments for measuring the severity of depression. It is a 21-item questionnaire for self-evaluation with 0-3 scores per item, ranging from 0 (normal state) to 63 (severe depression). | ClinicalTrials.gov |
| Secondary | Montreal Cognitive Assessment (MOCA) | Baseline - 1 week after stimulation - 1 month after stimulation | Montreal Cognitive Assessment (Nasreddine et al., 2005) is a clinical standard test for evaluating the following cognitive functions: visuospatial/executive, naming, memory, attention, language, abstraction, recall and orientation. The maximum score is 30 points. | ClinicalTrials.gov |
| Secondary | 36-Item Short Form Health Survey (SF-36) | Baseline - 1 week after stimulation - 1 month after stimulation | The 36-item short-form health survey (Ware et al., 1992) is a widely used instrument to measure quality of life. The 36-item patient-reported survey covers eight health concepts including physical functioning (10 items), role limitations due to physical health (4 items), role limitations due to emotional problems (3 items), energy/fatigue (4 items), emotional well-being (5 items), social functioning (2 items), pain (2 items), and general health (5 items). All questions are scored on a scale from 0 (worst health) to 100 (best health). | ClinicalTrials.gov |
| Secondary | Trail Making Test A and B (TMT-A and TMT-B) | Baseline - 1 week after stimulation - 1 month after stimulation | The Trail Making Test (Reitan et al., 1958) consist of two parts A and B. For each part, patients need to fulfill a task by connecting letters and/or numbers in the right way. The scoring of both parts is done by taking the time required to complete them. | ClinicalTrials.gov |
| Secondary | Positive and Negative Affect Schedule (PANAS) | Baseline - 1 week after stimulation - 1 month after stimulation | The Positive and Negative Affect Schedule (Watson et al., 1988) is an instrument to assess mood, specifically distinguishing between positive and negative affect. It has two subscales (positive and negative) and consists out of 20 items which are scored using a 5-point scale (1= not at all - 5 = extremely). | ClinicalTrials.gov |
| Secondary | Beck Anxiety Inventory (BAI) | Baseline - 1 week after stimulation - 1 month after stimulation | The Beck Anxiety Inventory (Beck et al., 1988) is a self-reported scale to measure anxiety. It consists of 21 items, which are scored from 0-3. The BAI has a total range from 0 to 63. | ClinicalTrials.gov |
| Secondary | Six Minute Walking Test (6MWT) | Baseline - 1 week after stimulation - 1 month after stimulation | The six-minute walking test, developed by the American Thoracic Society 2002, is an exercise test to assess aerobic capacity and endurance. The patients are asked to walk as far as they can within 6 minutes. Subjective tests (Borg-Scale, 0-10) will be administers before and after walking. | ClinicalTrials.gov |
| Secondary | Test of Attentional Performance (TAP) | Baseline - 1 week after stimulation - 1 month after stimulation | The Test of Attentional Performance (Zimmermann et al., 2002) is an instrument to measure attentional function. There are 14 subscales, including Sustained Attention, Vigilance, and Divided Attention. It will be carried out digitally using the TAP software package. | ClinicalTrials.gov |
| Secondary | Verbal Learning and Memory Test (VLMT) | Baseline - 1 week after stimulation - 1 month after stimulation | The German version of the Verbal Learning Memory Test by Helmstaedter and colleagues (2001) is an instrument to measure different parameters of declarative verbal memory such as learning or recognition performance. It consists of a learning phase, in which patients need to learn two lists of 15 words each, a delayed recall and a recognition test. | ClinicalTrials.gov |
| Secondary | Stroop color word test (STROOP) | Baseline - 1 week after stimulation - 1 month after stimulation | The Stroop Color-Word Test (Stroop, 1935) is a useful and reliable psychological assessment tool (Lezak, Howieson, \& Loring, 2004) that measures a person's ability to inhibit an automatic response in favor of an atypical one. Specifically, it involves identifying the ink color of incongruously labeled color words (van Boxtel et al., 2001). The test can measure cognitive performance functions such as naming speed, selectivity, and alertness (Bäumler \& Stroop, 1985). | ClinicalTrials.gov |
| Secondary | Satisfaction With Life Scale (SWLS) | Baseline - 1 week after stimulation - 1 month after stimulation | The SWLS (Satisfaction with Life Scale), developed by Diener and colleagues (1985), is a widely used self-report questionnaire designed to measure individuals' subjective satisfaction with their own lives. It consists of five items that capture different aspects of life satisfaction. | ClinicalTrials.gov |
| Secondary | Somatization subscale of the Symptom Check List-90-R (SCL-90-R SOM) | Baseline - 1 week after stimulation - 1 month after stimulation | The SCL-90-R (Schmitz et al., 2000) is a 90-item self-report symptom inventory used in clinical and research settings to evaluate psychological symptoms and distress. Only the SOM (Somatization) subscale within the SCL-90-R will be used for the present study. It consists of 12 items on a 5-point Likert scale that assess physical symptoms. The maximum score for the subscale is 48 points. | ClinicalTrials.gov |
| Secondary | Post-Exertional Malaise (BI-PEM) | Baseline - 1 week after stimulation - 1 month after stimulation | The German version of the DSQ PEM questionnaire (Cotler et al., 2018; Jason \& Sunnquist, 2018) comprises three subscales and a total of 11 items, focusing on post-exertional malaise. The subscales include questions concerning frequency, severity and duration of the symptoms after engaging in activities over the past 6 months. | ClinicalTrials.gov |
| Secondary | Neuroimaging | Baseline - 1 week after stimulation - 1 month after stimulation | Magnetic resonance imaging (MRI) will be recorded the week before, the week after and 1 month after TPS stimulations by center 1 (Vienna) for the Austrian study population. MR measurements will be performed using a 3 T SIEMENS PRISMA MR with a 64-channel head coil. MRI images will be obtained to assess changes in structural and functional brain connectivity. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 19
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 32042569 | BACKGROUND | PubMed |
| 33144403 | BACKGROUND | PubMed |
| 33681449 | BACKGROUND | PubMed |
| 34951953 | BACKGROUND | PubMed |
| 35033118 | BACKGROUND | PubMed |
| 35169611 | BACKGROUND | PubMed |
| 35215212 | BACKGROUND | PubMed |
| 35255491 | BACKGROUND | PubMed |
| 35383197 | BACKGROUND | PubMed |
| 35561960 | BACKGROUND | PubMed |
| 35668159 | BACKGROUND | PubMed |
| 35785594 | BACKGROUND | PubMed |
| 36188380 | BACKGROUND | PubMed |
| 36291211 | BACKGROUND | PubMed |
| 36385449 | BACKGROUND | PubMed |
| 36642173 | BACKGROUND | PubMed |
| 36693536 | BACKGROUND | PubMed |
| 36700201 | BACKGROUND | PubMed |
| 36961104 | BACKGROUND | PubMed |
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 3
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)